The U.S. Food and Drug Administration (FDA) has issued warnings to nine companies for selling 14 unapproved narcotic pain medicines as part of an ongoing effort to rid the market of drugs without proper approval. FDA officials said the widely used prescription medicines contained morphine, hydromorphone, or oxycodone. The companies--which include Boehringer Ingelheim's Roxane Inc unit, Covidien Ltd's Mallinckrodt unit, and Glenmark Pharmaceuticals--must stop manufacturing the unapproved...
Read moreVoluntary recalls were issued for specific lots of two opioid pain relievers and one medication for tension headaches. The affected drugs... Read more »
Full Question: A month ago I was diagnosed with ophthalmology migraine. I am taking 25mg of Topamax twice a day and Butalb acetamin- caff... Read more »
Full Question: I have what was called "silent" migraines with numbness in face, vision problems, auras, sometimes stomach is upset, and... Read more »
If you take a butalbital medication for your Migraines or another pain issue, you need to be aware of a recall by Qualitest... Read more »
It has been about ten years since the United States Drug Enforcement Administration (DEA) launched what some feel is a targeted war on... Read more »
This study will compare Trexima to to a butalbital-containing combination medication, acetaminophen, caffeine, and the butalbital med Fioricet in... Read more »
According to Canadian researchers, the number of deaths from opioid painkiller use has doubled since 1991, and they say the increased use and abuse... Read more »
Earlier this year, the U.S. Food and Drug Administration (FDA) presented the Risk Evaluation and Mitigation Strategy (REMS), a proposal designed to... Read more »
According to researchers at the University of Michigan, one in 10 high school seniors have used narcotic painkillers, though most of them use the... Read more »
Migraineurs and other chronic pain patients who use narcotics (opioids) are often asked to sign narcotics contracts, or treatment agreements, with... Read more »